
Sharon L. Turner
Examiner (ID: 4190, Phone: (571)272-0894 , Office: P/3991 )
| Most Active Art Unit | 1647 |
| Art Unit(s) | 1649, 1645, 3991, 1647, 1644 |
| Total Applications | 477 |
| Issued Applications | 225 |
| Pending Applications | 85 |
| Abandoned Applications | 167 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 19343507
[patent_doc_number] => 20240252470
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-08-01
[patent_title] => USE OF SUBLINGUAL DEXMEDETOMIDINE FOR THE TREATMENT OF AGITATION
[patent_app_type] => utility
[patent_app_number] => 18/436589
[patent_app_country] => US
[patent_app_date] => 2024-02-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 19805
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 114
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18436589
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/436589 | USE OF SUBLINGUAL DEXMEDETOMIDINE FOR THE TREATMENT OF AGITATION | Feb 7, 2024 | Abandoned |
Array
(
[id] => 19216138
[patent_doc_number] => 20240180842
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-06-06
[patent_title] => COLON TARGETED DRUG DELIVERY
[patent_app_type] => utility
[patent_app_number] => 18/525072
[patent_app_country] => US
[patent_app_date] => 2023-11-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 38150
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -8
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18525072
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/525072 | COLON TARGETED DRUG DELIVERY | Nov 29, 2023 | Abandoned |
Array
(
[id] => 18496046
[patent_doc_number] => 20230218580
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-07-13
[patent_title] => USE OF SUBLINGUAL DEXMEDETOMIDINE FOR THE TREATMENT OF AGITATION
[patent_app_type] => utility
[patent_app_number] => 18/124943
[patent_app_country] => US
[patent_app_date] => 2023-03-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 19793
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 59
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18124943
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/124943 | USE OF SUBLINGUAL DEXMEDETOMIDINE FOR THE TREATMENT OF AGITATION | Mar 21, 2023 | Abandoned |
Array
(
[id] => 18271867
[patent_doc_number] => 20230093109
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-03-23
[patent_title] => USE OF SUBLINGUAL DEXMEDETOMIDINE FOR THE TREATMENT OF AGITATION
[patent_app_type] => utility
[patent_app_number] => 17/990332
[patent_app_country] => US
[patent_app_date] => 2022-11-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 19819
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 59
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17990332
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/990332 | USE OF SUBLINGUAL DEXMEDETOMIDINE FOR THE TREATMENT OF AGITATION | Nov 17, 2022 | Abandoned |
Array
(
[id] => 18522807
[patent_doc_number] => 20230233456
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-07-27
[patent_title] => COMPOSITIONS AND METHODS FOR TREATING CORONAVIRUS
[patent_app_type] => utility
[patent_app_number] => 17/996545
[patent_app_country] => US
[patent_app_date] => 2022-03-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5394
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -44
[patent_words_short_claim] => 24
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17996545
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/996545 | COMPOSITIONS AND METHODS FOR TREATING CORONAVIRUS | Mar 20, 2022 | Abandoned |
Array
(
[id] => 17911213
[patent_doc_number] => 20220313608
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-10-06
[patent_title] => TREATMENT OF BREAST CANCER
[patent_app_type] => utility
[patent_app_number] => 17/655672
[patent_app_country] => US
[patent_app_date] => 2022-03-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10677
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17655672
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/655672 | TREATMENT OF BREAST CANCER | Mar 20, 2022 | Abandoned |
Array
(
[id] => 17702693
[patent_doc_number] => 20220202699
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-06-30
[patent_title] => COMPOSITIONS FOR THE TREATMENT OF VIRAL PULMONARY INFECTIONS
[patent_app_type] => utility
[patent_app_number] => 17/695464
[patent_app_country] => US
[patent_app_date] => 2022-03-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6200
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 20
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17695464
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/695464 | COMPOSITIONS FOR THE TREATMENT OF VIRAL PULMONARY INFECTIONS | Mar 14, 2022 | Abandoned |
Array
(
[id] => 17702694
[patent_doc_number] => 20220202700
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-06-30
[patent_title] => COMPOSITIONS FOR THE TREATMENT OF VIRAL PULMONARY INFECTIONS
[patent_app_type] => utility
[patent_app_number] => 17/695489
[patent_app_country] => US
[patent_app_date] => 2022-03-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6200
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 64
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17695489
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/695489 | COMPOSITIONS FOR THE TREATMENT OF VIRAL PULMONARY INFECTIONS | Mar 14, 2022 | Abandoned |
Array
(
[id] => 17702932
[patent_doc_number] => 20220202938
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-06-30
[patent_title] => TRANSDERMAL FORMULATIONS
[patent_app_type] => utility
[patent_app_number] => 17/654203
[patent_app_country] => US
[patent_app_date] => 2022-03-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 30177
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 68
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17654203
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/654203 | TRANSDERMAL FORMULATIONS | Mar 8, 2022 | Abandoned |
Array
(
[id] => 17850381
[patent_doc_number] => 20220280422
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-09-08
[patent_title] => SOLUBILIZED MELATONIN
[patent_app_type] => utility
[patent_app_number] => 17/650156
[patent_app_country] => US
[patent_app_date] => 2022-02-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8769
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 83
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17650156
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/650156 | SOLUBILIZED MELATONIN | Feb 6, 2022 | Abandoned |
Array
(
[id] => 17441920
[patent_doc_number] => 20220062425
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-03-03
[patent_title] => LIPONUCLEOTIDE-BASED THERAPY FOR COPD
[patent_app_type] => utility
[patent_app_number] => 17/472225
[patent_app_country] => US
[patent_app_date] => 2021-09-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8635
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 36
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17472225
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/472225 | LIPONUCLEOTIDE-BASED THERAPY FOR COPD | Sep 9, 2021 | Abandoned |
Array
(
[id] => 17354572
[patent_doc_number] => 20220015368
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-01-20
[patent_title] => BIOCIDAL SURFACE
[patent_app_type] => utility
[patent_app_number] => 17/347583
[patent_app_country] => US
[patent_app_date] => 2021-06-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11333
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17347583
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/347583 | BIOCIDAL SURFACE | Jun 13, 2021 | Abandoned |
Array
(
[id] => 18699464
[patent_doc_number] => 11785944
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-10-17
[patent_title] => Phenolic aerosol sprays comprising thymol
[patent_app_type] => utility
[patent_app_number] => 17/006830
[patent_app_country] => US
[patent_app_date] => 2020-08-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 1
[patent_figures_cnt] => 3
[patent_no_of_words] => 6173
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 49
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17006830
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/006830 | Phenolic aerosol sprays comprising thymol | Aug 28, 2020 | Issued |
Array
(
[id] => 20479285
[patent_doc_number] => 12527748
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2026-01-20
[patent_title] => Vapor phase coatings for pharmaceutical solubility control
[patent_app_type] => utility
[patent_app_number] => 17/636293
[patent_app_country] => US
[patent_app_date] => 2020-08-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 3
[patent_figures_cnt] => 3
[patent_no_of_words] => 1204
[patent_no_of_claims] => 15
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 150
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17636293
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/636293 | Vapor phase coatings for pharmaceutical solubility control | Aug 26, 2020 | Issued |
Array
(
[id] => 16655853
[patent_doc_number] => 20210052489
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-02-25
[patent_title] => PARTICLES, COMPOSITIONS AND METHODS FOR OPHTHALMIC AND/OR OTHER APPLICATIONS
[patent_app_type] => utility
[patent_app_number] => 16/945398
[patent_app_country] => US
[patent_app_date] => 2020-07-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 73106
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -24
[patent_words_short_claim] => 274
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16945398
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/945398 | PARTICLES, COMPOSITIONS AND METHODS FOR OPHTHALMIC AND/OR OTHER APPLICATIONS | Jul 30, 2020 | Abandoned |
Array
(
[id] => 16450874
[patent_doc_number] => 20200360300
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-11-19
[patent_title] => Suppression of Cytokine Release and Cytokine Storm
[patent_app_type] => utility
[patent_app_number] => 16/945195
[patent_app_country] => US
[patent_app_date] => 2020-07-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 20277
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 53
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16945195
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/945195 | Suppression of Cytokine Release and Cytokine Storm | Jul 30, 2020 | Abandoned |
Array
(
[id] => 17702789
[patent_doc_number] => 20220202795
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-06-30
[patent_title] => PHARMACEUTICAL COMPOSITION COMPRISING ESOMEPRAZOLE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND HAVING DOUBLE-RELEASE PROFILE
[patent_app_type] => utility
[patent_app_number] => 17/600639
[patent_app_country] => US
[patent_app_date] => 2020-04-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15937
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 120
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17600639
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/600639 | PHARMACEUTICAL COMPOSITION COMPRISING ESOMEPRAZOLE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND HAVING DOUBLE-RELEASE PROFILE | Mar 31, 2020 | Abandoned |
Array
(
[id] => 17609607
[patent_doc_number] => 20220151886
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-05-19
[patent_title] => MULTIPLE EMULSION COMPRISING AN OIL CONTINUOUS NANOEMULSION AND A METHOD FOR USING THE SAME
[patent_app_type] => utility
[patent_app_number] => 17/442224
[patent_app_country] => US
[patent_app_date] => 2020-03-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5260
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -10
[patent_words_short_claim] => 196
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17442224
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/442224 | MULTIPLE EMULSION COMPRISING AN OIL CONTINUOUS NANOEMULSION AND A METHOD FOR USING THE SAME | Mar 24, 2020 | Abandoned |
Array
(
[id] => 17519384
[patent_doc_number] => 20220105232
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-04-07
[patent_title] => COMPOSITE VISCOELASTIC HYDROGEL, AND USES THEREOF FOR SEALING A CHANNEL IN TISSUE
[patent_app_type] => utility
[patent_app_number] => 17/422106
[patent_app_country] => US
[patent_app_date] => 2020-01-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15814
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17422106
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/422106 | COMPOSITE VISCOELASTIC HYDROGEL, AND USES THEREOF FOR SEALING A CHANNEL IN TISSUE | Jan 9, 2020 | Pending |
Array
(
[id] => 17154154
[patent_doc_number] => 20210315205
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-10-14
[patent_title] => DICHALCOGENIDE TITANIUM OXIDE MATERIALS FOR DISINFECTION
[patent_app_type] => utility
[patent_app_number] => 17/272086
[patent_app_country] => US
[patent_app_date] => 2019-08-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9050
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17272086
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/272086 | DICHALCOGENIDE TITANIUM OXIDE MATERIALS FOR DISINFECTION | Aug 26, 2019 | Abandoned |